Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2014 Dec;99(12):E2709-14.
doi: 10.1210/jc.2014-2494.

Sulfonylurea treatment before genetic testing in neonatal diabetes: pros and cons

David Carmody  1 , Charles D Bell, Jessica L Hwang, Jazzmyne T Dickens, Daniela I Sima, Dania L Felipe, Carrie A Zimmer, Ajuah O Davis, Kateryna Kotlyarevska, Rochelle N Naylor, Louis H Philipson, Siri Atma W Greeley
Affiliations
Observational Study

Sulfonylurea treatment before genetic testing in neonatal diabetes: pros and cons

David Carmody et al. J Clin Endocrinol Metab. 2014 Dec.

Abstract

Context: Diabetes in neonates nearly always has a monogenic etiology. Earlier sulfonylurea therapy can improve glycemic control and potential neurodevelopmental outcomes in children with KCNJ11 or ABCC8 mutations, the most common gene causes.

Objective: Assess the risks and benefits of initiating sulfonylurea therapy before genetic testing results become available.

Design, setting, and patients: Observational retrospective study of subjects with neonatal diabetes within the University of Chicago Monogenic Diabetes Registry.

Main outcome measures: Response to sulfonylurea (determined by whether insulin could be discontinued) and treatment side effects in those treated empirically.

Results: A total of 154 subjects were diagnosed with diabetes before 6 months of age. A genetic diagnosis had been determined in 118 (77%), with 73 (47%) having a mutation in KCNJ11 or ABCC8. The median time from clinical diagnosis to genetic diagnosis was 10.4 weeks (range, 1.6 to 58.2 wk). In nine probands, an empiric sulfonylurea trial was initiated within 28 days of diabetes diagnosis. A genetic cause was subsequently found in eight cases, and insulin was discontinued within 14 days of sulfonylurea initiation in all of these cases.

Conclusions: Sulfonylurea therapy appears to be safe and often successful in neonatal diabetes patients before genetic testing results are available; however, larger numbers of cases must be studied. Given the potential beneficial effect on neurodevelopmental outcome, glycemic control, and the current barriers to expeditious acquisition of genetic testing, an empiric inpatient trial of sulfonylurea can be considered. However, obtaining a genetic diagnosis remains imperative to inform long-term management and prognosis.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Decision algorithm for an empiric trial of sulfonylurea. CNS, central nervous system; SU, sulfonylurea. International monogenic diabetes registries can be contacted (http://monogenicdiabetes.uchicago.edu and http://www.diabetesgenes.org) if local expert help is unavailable.
See this image and copyright information in PMC

Comment in

References

    1. Greeley SA, Tucker SE, Naylor RN, Bell GI, Philipson LH. Neonatal diabetes mellitus: a model for personalized medicine. Trends Endocrinol Metab. 2010;21:464–472. - PMC - PubMed
    1. Wiedemann B, Schober E, Waldhoer T, et al. Incidence of neonatal diabetes in Austria-calculation based on the Austrian Diabetes Register. Pediatr Diabetes. 2010;11:18–23. - PubMed
    1. Iafusco D, Massa O, Pasquino B, et al. Minimal incidence of neonatal/infancy onset diabetes in Italy is 1:90,000 live births. Acta Diabetol. 2012;49:405–408. - PMC - PubMed
    1. Flanagan SE, Edghill EL, Gloyn AL, Ellard S, Hattersley AT. Mutations in KCNJ11, which encodes Kir6.2, are a common cause of diabetes diagnosed in the first 6 months of life, with the phenotype determined by genotype. Diabetologia. 2006;49:1190–1197. - PubMed
    1. Edghill EL, Dix RJ, Flanagan SE, et al. HLA genotyping supports a nonautoimmune etiology in patients diagnosed with diabetes under the age of 6 months. Diabetes. 2006;55:1895–1898. - PubMed

Publication types

MeSH terms